At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 171–180 of 580 results.
-
In this study, researchers are comparing early treatment with venetoclax and obinutuzumab versus delayed treatment with these two medications in patients with newly diagnosed high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are not experiencing symptoms. Starting treatment with these drugs early (before patients have symptoms) may be more effective than delaying treatment until symptoms emerge.
-
The purpose of this study is to assess the safety and effectiveness of adding the drug evexomostat (SDX-7320) to standard eribulin chemotherapy in people with triple-negative breast cancer (TNBC) that has come back or spread despite treatment. In addition, the participants in this study have metabolic disorders such as high blood sugar and/or obesity. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
-
Researchers are assessing tepotinib with or without ramucirumab in people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has metastasized (spread) or recurred (came back) after treatment. Their cancers also have a genetic change called the MET exon 14 skipping mutation.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
-
Researchers want to find the best dose of eganelisib when used alone and with cytarabine to treat leukemia. The people in this study have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) that has come back or keeps growing after treatment.          
-
A standard approach for early-stage rectal cancer is treatment with chemotherapy and radiation therapy followed by surgery. In this study, researchers are comparing two approaches to prevent the need for rectal resection (removal of all or nearly all of the rectum) in people with early rectal cancer: chemotherapy or chemotherapy and radiation with observation or limited surgery (removing only the area with the tumor, not the entire rectum).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are assessing the use of cobimetinib to treat Langerhans cell histiocytosis (LCH) and other histiocytic disorders. Histiocytic disorders are diseases caused by the abnormal function or buildup of immune cells called histiocytes. Cobimetinib works by blocking the activity of a protein called MEK. This protein leads to the abnormal growth and development of histiocytosis cells.
-
Cancer and its treatment may affect sexual and reproductive health. The purpose of this study is to evaluate sexual and reproductive health over several years among women age 50 and younger newly diagnosed with breast cancer or lymphoma.